|
gptkbp:instance_of
|
gptkb:healthcare_organization
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:anaplastic_large_cell_lymphoma,_ALK-positive
|
|
gptkbp:affects
|
lymphatic system
|
|
gptkbp:associated_with
|
gptkb:healthcare_organization
|
|
gptkbp:can_lead_to
|
secondary cancers
|
|
gptkbp:clinical_trial
|
ongoing research
new therapies
combination treatments
|
|
gptkbp:first_described_by
|
gptkb:1980s
|
|
gptkbp:genetic_diversity
|
gptkb:ALK
T P53
C D30
JA K1
STA T3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
anaplastic lymphoma
|
|
gptkbp:is_characterized_by
|
large atypical lymphoid cells
|
|
gptkbp:is_found_in
|
gptkb:skincare_product
lungs
bone marrow
lymph nodes
spleen
|
|
gptkbp:is_often_used_in
|
adults
|
|
gptkbp:occurs_in
|
gptkb:HIV
autoimmune diseases
EBV infection
|
|
gptkbp:risk_factor
|
age
gender
immune system disorders
|
|
gptkbp:social_responsibility
|
rare
variable
imaging studies
more common in males
biopsy
incidence rate varies by region
|
|
gptkbp:symptoms
|
weight loss
fever
night sweats
swollen lymph nodes
|
|
gptkbp:treatment
|
gptkb:CHOP_regimen
gptkb:ICE_regimen
gptkb:brentuximab_vedotin
gptkb:vaccine
gptkb:municipality
gptkb:drug
survival rate
targeted therapies
radiation therapy
chemotherapy
relapse
remission
stem cell transplant
|
|
gptkbp:type_of
|
gptkb:ALK-positive_anaplastic_large_cell_lymphoma
gptkb:ALK-negative_anaplastic_large_cell_lymphoma
|